The global viral inactivation market reached USD 550 Million in 2021 and is expected to register a CAGR of 12.5% during the forecast period of 2022 to 2030. Regulatory authorities require viral inactivation testing for investigational new drug (IND) submission, and it is crucial for the process development of biologicals, such as tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, vaccines, and therapeutics. Rapid growth in the pharmaceutical and biotechnology sectors and a strong trend of R&D spending in the life sciences industry are the primary market drivers. Increasing government support for the pharmaceutical and biotechnology industries, as well as an increase in the prevalence of chronic diseases, will also contribute to the expansion of this industry. The rise in the number of pharmaceutical and biopharmaceutical companies worldwide, the rise in investment in the life sciences sector, the rise in the number of drug launches and approvals, and the rise in government funding for the development of the pharmaceutical and biopharmaceutical industries are among the major factors driving the market growth. The global growth in chronic diseases such as cancer, diabetes, autoimmune disorders, and other illnesses has contributed to an increase in healthcare costs. An increase in healthcare expenditures is required primarily to conceive and develop new and improved medications to combat the escalation of these diseases. Increasing R&D innovation, medication discoveries, and FDA approvals that culminate in the marketing of new drugs are driving market expansion.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
Rising Incidence of Chronic Diseases
A rise in the prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, as well as an increase in healthcare spending, are the primary drivers driving the growth of the viral inactivation market. In 2020, the 5-year prevalence of all types of malignancies in both sexes in Africa is projected to be 2,166,740. In addition, it has been stated that, of these cases, 1,298,101 were documented in females and 868,639 in males of all ages. Such a high incidence of cancer is driving market expansion over the projection period. Additionally, the same source indicated that the 5-year prevalence of cancer cases in Saudi Arabia is approximately 82,640 cases of all types of cancer in both sexes, with 39,241 male cases and 43,399 female cases reported in 2020. Increasing approvals from the Food and Medication Administration for drug candidates are also anticipated to fuel the expansion of the market under study. According to data published in Mid-Year Review: New Drug Approvals in June 2021, the United States Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) approved 26 New Molecular Entities (NMEs) at the halfway point of 2021 (as of June 28, 2021), which was comparable to the approval rate for the entire year of 2020, which was 53 NMEs. Except for 2018, when 59 NMEs were given, the number of NMEs approved in 2020 was the second highest in the previous decade, trailing only 2018's total of 59. Increasing FDA approvals will raise research and development activities, which in turn will necessitate toxicological screening studies. These studies are anticipated to promote the adoption of viral inactivation technologies, hence driving the expansion of this market. Thus, the aforementioned elements are anticipated to stimulate market expansion.Kits and Reagents Dominate the Product Market
The market is segmented by product into kits & reagents, systems, and services. Due to the continued use of kits and reagents by pharmaceutical and biopharmaceutical businesses, kits and reagents held the greatest market share in 2021. Due to the simplicity of management and specialized services provided by service-providing organizations, the services industry is expected to grow at the highest rate. With a surge in the number of pharmaceutical and biopharmaceutical businesses and spending on research and development for new medication development, the demand for kits and reagents has skyrocketed. Due to the rising use of consumables, kits, and reagents in a variety of end-use settings, this was the largest market sector for the product.Vaccines and Therapeutics Segment to Dominate the Application Market
The viral inactivation market is categorized by application into vaccines and treatments, stem cell products, blood and blood tissue products, tissue and tissue products, and cellular and gene therapy products. The vaccine and therapeutics sector held the largest revenue share in 2021. The highest market revenue is attributable to higher incidences and the enormous economic burden of chronic diseases such as Cancer, which demanded inactivated vaccines and increased government support for pharmaceutical and biotechnology industries to invest in the research and development of novel therapeutics. In 2020, the International Agency for Research on Cancer (Globocan) reported that 495,773 new cases of pancreatic cancer were detected worldwide. According to GLOBOCAN 2020 data, the incidence of new pancreatic cancer cases in countries with a very high HDI (Human Development Index) was 275,036, followed by 187,205 in countries with a high HDI. There were 24,705 and 8,586 cases in nations with medium and low HDI, respectively. Similarly, rising activities by industry participants are anticipated to support market expansion. Prestige Biopharma (PBP), a Singapore-based biopharmaceutical business, announced in March 2022 that its Innovative Discovery Centre (IDC) is being constructed in Busan, South Korea. The IDC will guide PBP's future vision through initiatives such as the development of antibody therapies, including treatments for pancreatic cancer, and cutting-edge vaccination technology. In addition, there are efforts to create pancreatic cancer-treating vaccinations. In October 2020, experts from the Francis Crick Institute in London, United Kingdom, revealed an experimental vaccination based on immunotherapy that targets the KRAS gene, which is implicated in the development of numerous types of cancer. Thus, the aforementioned elements are anticipated to stimulate market expansion.Pharma and BioPharma Segment Dominate the End User Segment
Based on end-use, the viral inactivation market is segmented into pharmaceutical and biopharmaceutical firms, contract research organizations (CROs), academic and research institutions, and others. In addition, laboratories and blood banks are also considered to be medical suppliers. Due to the rising use of these items in medication development and drug manufacturing, the pharmaceutical and biopharmaceutical industries held the highest market share in 2021. In the past few decades, the pharmaceutical and biopharmaceutical industries have experienced tremendous expansion. The number of new pharmaceuticals has increased as a result of a rise in funding for the discovery of alternative therapies. With the emergence of biologics and other cellular and gene therapy products, pharmaceutical and biopharmaceutical companies have increased their use of viral inactivation products. The product's safety for human usage is ensured by stringent regulatory criteria for therapeutic agents. Biopharmaceutical businesses frequently use strategies such as solvent detergent, low pH, pasteurization, and other measures to ensure the safety of their products. Companies use single-use systems or bioreactors to carry out these treatments and inactivate viruses.North America Remains as the Global Leader
Throughout the forecast period, North America held the dominant position in 2021. The U.S. remained the largest revenue share in North America. In addition, the advanced healthcare infrastructure, the presence of large pharmaceutical and biopharmaceutical businesses, and the significant healthcare R&D expenditures by the government and companies in the United States are expected to drive the North American market. According to ClinicalTrial.gov, Canadian pharmaceutical companies and research institutions had robust R&D pipelines in 2021, with 5,659 new studies in various stages of evaluation, 1,397 (24%) of which were in Phase III clinical trials approved by the food and drug administration (FDA) or EMA (European Medicines Agency), representing a broad range of therapeutic areas; this condition will stimulate market growth in the country. The Plan to Mobilize Science in 2020 of the Canadian government contains USD 192 million for coronavirus research and medical countermeasures, as well as up to USD 56 million for clinical trials of a COVID-related vaccine candidate from Variations Biotechnology Inc. Mexico plans to release its National Pharmaceutical Policy in April 2022, which will address a variety of supply chain and regulatory challenges, and the framework collaboration agreements signed by Mexico will strengthen scientific research and foster pharmaceutical innovation, which will lead to an increase in the number of drug discoveries in the country, thereby increasing the country's economy. In addition, with additional funding from Michigan Drug Discovery in 2021, researchers from throughout the University of Michigan are investigating methods to treat pain, cancer, and infection. The market is driven by the fact that four of the five studies will seek novel physiologically active chemicals that can be used to target essential drug discovery targets. As a result of the aforementioned factors, it is anticipated that the studied market would expand more rapidly throughout the forecast period.Market Moving towards Consolidation during the Forecast Period
The market for viral inactivation is moderately concentrated and competitive, with many significant competitors. In terms of market share, a small number of market leaders are now utilizing a variety of development methods to dominate the industry. Some important firms are consolidating their global market positions through strategic acquisitions and mergers. In addition, it is anticipated that new players will enter the market with unique product pipelines and ongoing technological advancements that will raise market revenue throughout the projection period. The bulk of participants is focusing on new product development. The market is characterized by numerous mergers and acquisitions, resulting in a high degree of market consolidation. The major players in this market include Merck & Co., Inc., PARKER HANNIFIN CORP, Sartorius AG, Texcell, Cytiva, Danaher., SGS SA, Charles River Laboratories., Cleancells, Rad Source Technologies, WuXiAppTec, GENERAL ELECTRIC COMPANY, Sigma-Aldrich Co., Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, and others.Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Viral Inactivation market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Viral Inactivation market and their expected impact during the forecast period.
Market Segmentation
Method
- Solvent Detergent Method
- Pasteurization
- Other Viral Inactivation Method
Product
- Kits and Reagents
- Services
- Viral Inactivation Systems and Accessories
Application
- Blood & Blood Products
- Cellular & Gene Therapy Products
- Stem Cell Products
- Tissue & Tissue Products
- Vaccines and Therapeutics
End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutes
- Other End Users
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Viral Inactivation market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Viral Inactivation market?
- Which is the largest regional market for Viral Inactivation market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Viral Inactivation market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Viral Inactivation market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Viral Inactivation Market
2.2. Global Viral Inactivation Market, By Method, 2021 (US$ Million)
2.3. Global Viral Inactivation Market, By Product, 2021 (US$ Million)
2.4. Global Viral Inactivation Market, By Application, 2021 (US$ Million)
2.5. Global Viral Inactivation Market, By End User, 2021 (US$ Million)
2.6. Global Viral Inactivation Market, By Geography, 2021 (US$ Million)
2.7. Attractive Investment Proposition by Geography, 2021
3. Viral Inactivation Market: Competitive Analysis
3.1. Market Positioning of Key Viral Inactivation Market Vendors
3.2. Strategies Adopted by Viral Inactivation Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Viral Inactivation Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Viral Inactivation Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Solvent Detergent Method
5.3.2. Pasteurization
5.3.3. Other Viral Inactivation Method
6. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Kits and Reagents
6.3.2. Services
6.3.3. Viral Inactivation Systems and Accessories
7. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2021 Versus 2030
7.3. Market Segmentation
7.3.1. Blood & Blood Products
7.3.2. Cellular & Gene Therapy Products
7.3.3. Stem Cell Products
7.3.4. Tissue & Tissue Products
7.3.5. Vaccines and Therapeutics
8. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Growth & Revenue Analysis: 2021 Versus 2030
8.3. Market Segmentation
8.3.1. Pharmaceutical and Biotechnology Companies
8.3.2. Contract Research Organizations
8.3.3. Academic Research Institutes
8.3.4. Other End Users
9. North America Viral Inactivation Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
9.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
9.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
9.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
9.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
9.6.1.North America
9.6.1.1. U.S.
9.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
9.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
9.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
9.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
9.6.1.2. Canada
9.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
9.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
9.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
9.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
9.6.1.3. Rest of North America
9.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
9.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
9.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
9.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
10. UK and European Union Viral Inactivation Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
10.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
10.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
10.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
10.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
10.6.1.UK and European Union
10.6.1.1. UK
10.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
10.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
10.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
10.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
10.6.1.2. Germany
10.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
10.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
10.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
10.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
10.6.1.3. Spain
10.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
10.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
10.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
10.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
10.6.1.4. Italy
10.6.1.4.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
10.6.1.4.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
10.6.1.4.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
10.6.1.4.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
10.6.1.5. France
10.6.1.5.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
10.6.1.5.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
10.6.1.5.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
10.6.1.5.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
10.6.1.6. Rest of Europe
10.6.1.6.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
10.6.1.6.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
10.6.1.6.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
10.6.1.6.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
11. Asia Pacific Viral Inactivation Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
11.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
11.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
11.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
11.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
11.6.1.Asia Pacific
11.6.1.1. China
11.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
11.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
11.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
11.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
11.6.1.2. Japan
11.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
11.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
11.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
11.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
11.6.1.3. India
11.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
11.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
11.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
11.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
11.6.1.4. Australia
11.6.1.4.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
11.6.1.4.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
11.6.1.4.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
11.6.1.4.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
11.6.1.5. South Korea
11.6.1.5.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
11.6.1.5.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
11.6.1.5.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
11.6.1.5.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
11.6.1.6. Rest of Asia Pacific
11.6.1.6.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
11.6.1.6.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
11.6.1.6.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
11.6.1.6.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
12. Latin America Viral Inactivation Market, 2020-2030, USD (Million)
12.1. Market Overview
12.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
12.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
12.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
12.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
12.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
12.6.1.Latin America
12.6.1.1. Brazil
12.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
12.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
12.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
12.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
12.6.1.2. Mexico
12.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
12.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
12.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
12.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
12.6.1.3. Rest of Latin America
12.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
12.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
12.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
12.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
13. Middle East and Africa Viral Inactivation Market, 2020-2030, USD (Million)
13.1. Market Overview
13.2. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
13.3. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
13.4. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
13.5. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
13.6.Viral Inactivation Market: By Region, 2020-2030, USD (Million)
13.6.1.Middle East and Africa
13.6.1.1. GCC
13.6.1.1.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
13.6.1.1.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
13.6.1.1.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
13.6.1.1.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
13.6.1.2. Africa
13.6.1.2.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
13.6.1.2.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
13.6.1.2.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
13.6.1.2.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
13.6.1.3. Rest of Middle East and Africa
13.6.1.3.1. Viral Inactivation Market: By Method, 2020-2030, USD (Million)
13.6.1.3.1. Viral Inactivation Market: By Product, 2020-2030, USD (Million)
13.6.1.3.1. Viral Inactivation Market: By Application, 2020-2030, USD (Million)
13.6.1.3.1. Viral Inactivation Market: By End User, 2020-2030, USD (Million)
14. Company Profile
14.1. Merck & Co., Inc.
14.1.1. Company Overview
14.1.2. Financial Performance
14.1.3. Product Portfolio
14.1.4. Strategic Initiatives
14.2. PARKER HANNIFIN CORP
14.2.1. Company Overview
14.2.2. Financial Performance
14.2.3. Product Portfolio
14.2.4. Strategic Initiatives
14.3. Sartorius AG
14.3.1. Company Overview
14.3.2. Financial Performance
14.3.3. Product Portfolio
14.3.4. Strategic Initiatives
14.4. Texcell
14.4.1. Company Overview
14.4.2. Financial Performance
14.4.3. Product Portfolio
14.4.4. Strategic Initiatives
14.5. Cytiva
14.5.1. Company Overview
14.5.2. Financial Performance
14.5.3. Product Portfolio
14.5.4. Strategic Initiatives
14.6. Danaher.
14.6.1. Company Overview
14.6.2. Financial Performance
14.6.3. Product Portfolio
14.6.4. Strategic Initiatives
14.7. SGS SA
14.7.1. Company Overview
14.7.2. Financial Performance
14.7.3. Product Portfolio
14.7.4. Strategic Initiatives
14.8. Charles River Laboratories.
14.8.1. Company Overview
14.8.2. Financial Performance
14.8.3. Product Portfolio
14.8.4. Strategic Initiatives
14.9. Cleancells
14.9.1. Company Overview
14.9.2. Financial Performance
14.9.3. Product Portfolio
14.9.4. Strategic Initiatives
14.10. Rad Source Technologies
14.10.1. Company Overview
14.10.2. Financial Performance
14.10.3. Product Portfolio
14.10.4. Strategic Initiatives
14.11. WuXiAppTec
14.11.1. Company Overview
14.11.2. Financial Performance
14.11.3. Product Portfolio
14.11.4. Strategic Initiatives
14.12. GENERAL ELECTRIC COMPANY
14.12.1. Company Overview
14.12.2. Financial Performance
14.12.3. Product Portfolio
14.12.4. Strategic Initiatives
14.13. Sigma-Aldrich Co.
14.13.1. Company Overview
14.13.2. Financial Performance
14.13.3. Product Portfolio
14.13.4. Strategic Initiatives
14.14. Thermo Fisher Scientific Inc.
14.14.1. Company Overview
14.14.2. Financial Performance
14.14.3. Product Portfolio
14.14.4. Strategic Initiatives
14.15. Macopharma
14.15.1. Company Overview
14.15.2. Financial Performance
14.15.3. Product Portfolio
14.15.4. Strategic Initiatives
14.16. Cerus Corporation
14.16.1. Company Overview
14.16.2. Financial Performance
14.16.3. Product Portfolio
14.16.4. Strategic Initiatives
14.17. Others
14.17.1. Company Overview
14.17.2. Financial Performance
14.17.3. Product Portfolio
14.17.4. Strategic Initiatives
List of Figures
Figure 1 Global Viral Inactivation Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Viral Inactivation Market: Quality Assurance
Figure 5 Global Viral Inactivation Market, By Method, 2021
Figure 6 Global Viral Inactivation Market, By Product, 2021
Figure 7 Global Viral Inactivation Market, By Application, 2021
Figure 8 Global Viral Inactivation Market, By End User, 2021
Figure 9 Global Viral Inactivation Market, By Geography, 2021
Figure 10 Market Geographical Opportunity Matrix - Global Viral Inactivation Market, 2021
Figure 11 Market Positioning of Key Viral Inactivation Market Players, 2021
Figure 12 Global Viral Inactivation Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 13 Global Viral Inactivation Market, By Method, 2021 Vs 2030, %
Figure 14 Global Viral Inactivation Market, By Product, 2021 Vs 2030, %
Figure 15 Global Viral Inactivation Market, By Application, 2021 Vs 2030, %
Figure 16 Global Viral Inactivation Market, By End User, 2021 Vs 2030, %
Figure 17 U.S. Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 18 Canada Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 19 Rest of North America Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 20 UK Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 21 Germany Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 22 Spain Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 23 Italy Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 24 France Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 25 Rest of Europe Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 26 China Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 27 Japan Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 28 India Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 29 Australia Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 30 South Korea Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 31 Rest of Asia Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 32 Brazil Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 33 Mexico Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 34 Rest of Latin America Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 35 GCC Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 36 Africa Viral Inactivation Market (US$ Million), 2020 - 2030
Figure 37 Rest of Middle East and Africa Viral Inactivation Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 2 Global Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 3 Global Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 4 Global Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 5 North America Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 6 North America Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 7 North America Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 8 North America Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 9 U.S. Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 10 U.S. Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 11 U.S. Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 12 U.S. Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 13 Canada Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 14 Canada Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 15 Canada Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 16 Canada Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 17 Rest of North America Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 18 Rest of North America Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 19 Rest of North America Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 20 Rest of North America Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 21 UK and European Union Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 22 UK and European Union Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 23 UK and European Union Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 24 UK and European Union Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 25 UK Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 26 UK Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 27 UK Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 28 UK Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 29 Germany Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 30 Germany Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 31 Germany Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 32 Germany Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 33 Spain Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 34 Spain Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 35 Spain Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 36 Spain Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 37 Italy Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 38 Italy Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 39 Italy Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 40 Italy Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 41 France Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 42 France Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 43 France Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 44 France Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 45 Rest of Europe Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 46 Rest of Europe Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 47 Rest of Europe Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 48 Rest of Europe Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 49 Asia Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 50 Asia Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 51 Asia Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 52 Asia Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 53 China Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 54 China Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 55 China Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 56 China Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 57 Japan Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 58 Japan Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 59 Japan Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 60 Japan Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 61 India Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 62 India Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 63 India Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 64 India Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 65 Australia Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 66 Australia Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 67 Australia Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 68 Australia Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 69 South Korea Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 70 South Korea Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 71 South Korea Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 72 South Korea Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 73 Latin America Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 74 Latin America Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 75 Latin America Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 76 Latin America Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 77 Brazil Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 78 Brazil Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 79 Brazil Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 80 Brazil Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 81 Mexico Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 82 Mexico Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 83 Mexico Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 84 Mexico Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 85 Rest of Latin America Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 86 Rest of Latin America Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 87 Rest of Latin America Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 88 Rest of Latin America Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 89 Middle East and Africa Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 90 Middle East and Africa Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 91 Middle East and Africa Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 92 Middle East and Africa Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 93 GCC Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 94 GCC Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 95 GCC Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 96 GCC Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 97 Africa Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 98 Africa Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 99 Africa Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 100 Africa Viral Inactivation Market By End User, 2020-2030, USD (Million)
Table 101 Rest of Middle East and Africa Viral Inactivation Market By Method, 2020-2030, USD (Million)
Table 102 Rest of Middle East and Africa Viral Inactivation Market By Product, 2020-2030, USD (Million)
Table 103 Rest of Middle East and Africa Viral Inactivation Market By Application, 2020-2030, USD (Million)
Table 104 Rest of Middle East and Africa Viral Inactivation Market By End User, 2020-2030, USD (Million)
Companies Mentioned
- Merck & Co. Inc.
- PARKER HANNIFIN CORP
- Sartorius AG
- Texcell
- Cytiva
- Danaher.
- SGS SA
- Charles River Laboratories.
- Cleancells
- Rad Source Technologies
- WuXiAppTec
- GENERAL ELECTRIC COMPANY
- Sigma-Aldrich Co.
- Thermo Fisher Scientific Inc.
- Macopharma
- Cerus Corporation
